Kelyniam Global (OTC: KLYG), a custom cranial implant manufacturer, reported challenging Q1 2025 results with revenue declining 34.7% to $624,910 from $957,447 in Q1 2024. The company posted an operating loss of $(140,556) compared to a profit of $123,599 in the prior year. To address these challenges, Kelyniam appointed Alex Rivero as National Sales Director and plans to add 10 new distributors in 2025.The company announced a significant three-year distribution agreement with Osteopore Ltd. to distribute their bioresorbable products in the U.S., including Osteostrip®, Osteoplug®, and Osteomesh®. This partnership, along with Finceramica, positions Kelyniam as a leader in regenerative medicine for cranial surgery while maintaining their commitment to 24-48 hour custom implant delivery.Read More
Kelyniam Global Announces Q1 2025 Financial Results and Strategic Partnership
By StockTitan
